临床试验/NCT00267280

NCT00267280终止3 期

A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)

Pfizer50 个研究点分布在 1 个国家目标入组 640 人开始时间: 2006年1月1日最近更新: 2012年2月17日

适应症

试验速览

阶段: 3 期
状态: 终止
发起方: Pfizer
入组人数: 640
试验地点: 50
主要终点: Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

详细描述

For additional information please call: 1-800-718-1021

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•eligible for statin treatment for LDL cholesterol by NCEP guidelines

排除标准

•Women who are pregnant or lactating, or planning to become pregnant.
•Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
•Subjects with significant liver or kidney disease or significant heart failure.

结局指标

主要结局

Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.

次要结局

Changes in other lipid parameters and other biomarkers.

研究者

发起方

Pfizer

申办方类型

Industry

责任方

Sponsor

研究点 (50)

Loading locations...

相似试验

已完成

3 期

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.HypercholesterolemiaDyslipidemiaHyperlipidemia

NCT00267254Pfizer640

终止

3 期

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.DyslipidemiaHyperlipidemia

NCT00267267Pfizer1,784

已完成

3 期

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High CholesterolHyperlipidemia

NCT00138762Pfizer3,800

已完成

3 期

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart DiseaseCoronary DiseaseCoronary ArteriosclerosisHyperlipidemia

NCT00134173Pfizer1,100

终止

3 期

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart DiseaseCoronary DiseaseDiabetes Mellitus

NCT00134264Pfizer15,067